This week's Pharma Pulse covers the launch of Medicare's GLP-1 Bridge, FDA's approval of the first regulatory T-cell therapy for chronic GVHD, seven companies tapped for FDA's PreCheck manufacturing ...
Deanna Horner, EVP of Enterprise DIRECT Strategy at EVERSANA, breaks down what's fueling pharma's embrace of direct-to-patient models. The direct-to-patient (DTP) channel has moved from experimental ...
Gerren McHam of the API Innovation Center outlines what a whole-of-government approach to meaningful pharmaceutical supply ...
Active shortages reached 323 in Q1 2024, with persistent durations and major chemotherapy impact; the burden includes rationing, delayed/canceled care, and substantial hospital labor costs. Generic ...
China's 2026 supply chain rules mean routine US trade compliance can now trigger Chinese export restrictions. China's new pharmaceutical supply chain regulations have transformed a chronic ...
As health technology assessment (HTA) requirements evolve and joint clinical assessments (JCA) reshape Europe, pharma companies face growing pressure to align evidence, access, and strategy earlier in ...
GEODIS validated paper-based thermal covers in 86 real-world lanes, demonstrating temperature robustness in diverse climates while targeting recyclability versus incumbent foil/aluminum solutions.
As health technology assessment (HTA) requirements evolve and joint clinical assessments (JCA) reshape Europe, pharma companies face growing pressure to align evidence, access, and strategy earlier in ...
In this week's Pharma Pulse, UPS commits $48 million to cold chain infrastructure, AbbVie moves to acquire Apogee Therapeutics in a $10.9 billion deal, and more. Welcome to Pharma Pulse, a ...
Market expansion is being fueled by high-cost specialty launches and persistent access friction, amid substantial adherence-related system costs and low first-year fill rates driven by payer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results